Resveratrol has been shown to protect against HFHS-induced decreases in hepatic LDLR and SR-BI gene and protein expressions, providing new insights into its pharmacological targets in MASLD prevention [65]. The gene discussed is SCARB1; the disease is metabolic dysfunction-associated steatotic liver disease.